DK3833786T5 - Rekombinant nucleinsyrekonstrukt - Google Patents

Rekombinant nucleinsyrekonstrukt Download PDF

Info

Publication number
DK3833786T5
DK3833786T5 DK19749727.4T DK19749727T DK3833786T5 DK 3833786 T5 DK3833786 T5 DK 3833786T5 DK 19749727 T DK19749727 T DK 19749727T DK 3833786 T5 DK3833786 T5 DK 3833786T5
Authority
DK
Denmark
Prior art keywords
nucleic acid
acid construct
recombinant nucleic
recombinant
construct
Prior art date
Application number
DK19749727.4T
Other languages
English (en)
Other versions
DK3833786T3 (da
Inventor
Klaus Giese
Oliver Keil
Jörg Kaufmann
Original Assignee
Pantherna Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18188489.1A external-priority patent/EP3608426A1/en
Application filed by Pantherna Therapeutics Gmbh filed Critical Pantherna Therapeutics Gmbh
Application granted granted Critical
Publication of DK3833786T3 publication Critical patent/DK3833786T3/da
Publication of DK3833786T5 publication Critical patent/DK3833786T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK19749727.4T 2018-08-10 2019-08-07 Rekombinant nucleinsyrekonstrukt DK3833786T5 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18188489.1A EP3608426A1 (en) 2018-08-10 2018-08-10 Recombinant nucleic acid construct
EP18194023 2018-09-12
EP18248243 2018-12-28
PCT/EP2019/071173 WO2020030672A1 (en) 2018-08-10 2019-08-07 Recombinant nucleic acid construct

Publications (2)

Publication Number Publication Date
DK3833786T3 DK3833786T3 (da) 2024-03-04
DK3833786T5 true DK3833786T5 (da) 2024-08-19

Family

ID=67544260

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19749727.4T DK3833786T5 (da) 2018-08-10 2019-08-07 Rekombinant nucleinsyrekonstrukt

Country Status (17)

Country Link
US (1) US12516348B2 (da)
EP (1) EP3833786B1 (da)
JP (1) JP7663494B2 (da)
KR (1) KR102811229B1 (da)
CN (1) CN112567053A (da)
AU (1) AU2019319035A1 (da)
BR (1) BR112021002333A2 (da)
DK (1) DK3833786T5 (da)
ES (1) ES2970185T3 (da)
FI (1) FI3833786T3 (da)
HU (1) HUE066311T2 (da)
IL (1) IL280157A (da)
MX (1) MX2021001547A (da)
PL (1) PL3833786T3 (da)
SG (1) SG11202100455WA (da)
WO (1) WO2020030672A1 (da)
ZA (1) ZA202100242B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865122A1 (en) * 2020-02-11 2021-08-18 Pantherna Therapeutics GmbH Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium
WO2022106072A1 (en) 2020-11-18 2022-05-27 Aplicacion Y Suministros Textiles, S.A.U. Textile stone washing process
WO2022110010A1 (zh) * 2020-11-27 2022-06-02 苏州吉玛基因股份有限公司 免疫激活剂、抗原和抗体在制备预防、治疗肿瘤产品中的应用
WO2026033123A1 (en) * 2024-08-08 2026-02-12 Sanofi Pasteur Inc. Lipid nanoparticle formulations for mrna delivery

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5318299A (en) * 1998-07-27 2000-02-21 Valentis, Inc. Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
GB9905498D0 (en) 1999-03-11 1999-05-05 Glaxo Group Ltd Expression
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
MX2011013457A (es) * 2009-06-15 2012-05-08 Biokine Therapeutics Ltd Polipeptidos que enlazan quimioquina novedosos capaces de inhibir el curso de autoinmunidad, inflamacion y cancer.
RU2573409C2 (ru) 2009-11-04 2016-01-20 Дзе Юниверсити Оф Бритиш Коламбиа Содержащие нуклеиновые кислоты липидные частицы и относящиеся к ним способы
EP2697368B1 (en) * 2011-04-15 2019-06-05 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
AU2014375402B2 (en) 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
EP4023755B1 (en) * 2014-12-12 2023-04-26 CureVac SE Artificial nucleic acid molecules for improved protein expression
US12258567B2 (en) * 2015-08-28 2025-03-25 CureVac SE Artificial nucleic acid molecules
WO2017100551A1 (en) 2015-12-09 2017-06-15 Alexion Pharmaceuticals, Inc. HETEROLOGOUS UTR SEQUENCES FOR ENHANCED mRNA EXPRESSION
WO2017201332A1 (en) * 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
WO2018115525A1 (en) * 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine

Also Published As

Publication number Publication date
CN112567053A (zh) 2021-03-26
EP3833786B1 (en) 2023-12-27
KR20210044240A (ko) 2021-04-22
JP7663494B2 (ja) 2025-04-16
AU2019319035A1 (en) 2021-02-04
BR112021002333A2 (pt) 2021-05-04
US12516348B2 (en) 2026-01-06
KR102811229B1 (ko) 2025-05-21
IL280157A (en) 2021-03-01
EP3833786A1 (en) 2021-06-16
PL3833786T3 (pl) 2024-05-06
CA3108670A1 (en) 2020-02-13
MX2021001547A (es) 2021-06-23
SG11202100455WA (en) 2021-02-25
JP2021533821A (ja) 2021-12-09
FI3833786T3 (fi) 2024-03-15
US20210261980A1 (en) 2021-08-26
WO2020030672A1 (en) 2020-02-13
DK3833786T3 (da) 2024-03-04
ZA202100242B (en) 2022-05-25
ES2970185T3 (es) 2024-05-27
HUE066311T2 (hu) 2024-07-28

Similar Documents

Publication Publication Date Title
EP3987019A4 (en) Barcode-based nucleic acid sequence assembly
UA42395S (uk) Футляр
PL3649151T3 (pl) Białka rusztowania
EP4023176C0 (en) STABILIZER
IL254516B (en) Proteins specific for cd137
IL254000B (en) Nucleic acid sequence assembly
DK3371310T3 (da) Nucleinsyrekonstruerede targetnucleinsyrer
EP3362556C0 (en) POLYPEPTIDE VARIANTS
HUE056911T2 (hu) Genetikai konstrukció
EP3828822C0 (en) CIVIL ENGINEERING
EP3986014A4 (en) TERMINAL
DK3784047T3 (da) Gærproteiner
EP3808783A4 (en) Novel crosslinked alginic acid
HUE056166T2 (hu) Új rovargátló fehérjék
DK3737402T5 (da) Modificeret protein
EP3769769A4 (en) REDUCED TOXICITY NUCLEIC ACID
DK3946179T3 (da) Stomiposer
EP3619311C0 (en) DNA ASSEMBLY
ZA202100242B (en) Recombinant nucleic acid construct
DK3630961T3 (da) Genetisk konstrukt
DK3840767T5 (da) Peptider
DK3663407T3 (da) Fremgangsmåde til nukleinsyresekvensering
PL3755363T3 (pl) Warianty plantarycyny nc8alfabeta
GB201812474D0 (en) Nucleic acid construct
EP4032551A4 (en) NUCLEIC ACID COMPLEX